Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause Atopic Dermatitis Provider Toolkit Adult Immunization Provider Toolkit Dermatology Hot Topics

MASLD/MASH

>

Latest News

Semaglutide 2.4 mg Approved for Treatment of MASH Without Cirrhosis: Daily Dose / image credit: ©New Africa/AdobeStock

Semaglutide 2.4 mg Approved for Treatment of MASH Without Cirrhosis: Daily Dose

By Sydney Jennings

August 26th 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis

FDA Approves Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis

By Patient Care Editorial Staff

August 16th 2025

Bariatric Surgery Lowers Risk of Liver Complications in Patients with Cirrhosis, Obesity

Bariatric Surgery Lowers Risk of Liver Complications in Patients with Cirrhosis, Obesity

By Sydney Jennings

January 28th 2025

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.